This study demonstrates that the selective LPAR1 antagonist PIPE-791 delivers potent antifibrotic activity across primary human lung fibroblasts, precision-cut lung slices from patients with pulmonary fibrosis and multiple in vivo models of lung fibrosis. PIPE-791 reduced collagen production, inhibited myofibroblast transformation, decreased profibrotic gene expression and secreted remodeling biomarkers in human lung tissue, and significantly lowered lung collagen and inflammatory markers in bleomycin-induced models. For AnaBios, these findings reinforce the strategic value of human, tissue-based platforms to generate translationally relevant data that strengthens target validation, improves confidence in mechanism and supports more informed advancement of antifibrotic therapies into the clinic.

PUBLICATION: Respiratory Research  (2026)

NOTE: AnaBios precision-cut lung slices were used in this study.